MLTX250516P30000
- 1.75
- 0.000.00%
MoonLake Immunotherapeutics Newsroom
MoonLake Immunotherapeutics Price Target Raised to $85 From $81 at BTIG
MoonLake Immunotherap Price Target Maintained With a $66.00/Share by Needham
Express News | Needham Reiterates Buy on MoonLake, Maintains $66 Price Target
MoonLake Immunotherapeutics: Promising Clinical Trials and Market Potential Drive Buy Rating
MoonLake Immunotherapeutics Announces Virtual Capital Markets Day on April 29, 2025, to Discuss Financial and Clinical Milestones
MoonLake Immunotherapeutics to Host a Capital Markets Day on Tuesday, April 29
Catalyst Watch: Apple, Amazon & Microsoft's Earnings Confessions, Meta's LlamaCon and the Jobs Report
Stifel Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $77
MoonLake Immunotherapeutics (NASDAQ:MLTX) Is In A Good Position To Deliver On Growth Plans
Cantor Fitzgerald Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating
MoonLake Obtains $500 Million Facility From Hercules Capital
MoonLake Immunotherapeutics Secures up to $500M in Non-dilutive Financing
MoonLake Secures up to $500 Million in Non-Dilutive Financing From Hercules Capital and Announces a Capital Markets Update on April 29 to Provide Important Clinical Updates
BTIG Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $81
Guggenheim Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $80
RBC Capital Initiates MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Announces Target Price $67
New Analyst Forecast: $MLTX Given $67.0 Price Target
MoonLake Immunotherap Price Target Announced at $67.00/Share by RBC Capital
This West Pharmaceutical Services Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
MoonLake Earns New Outperform at RBC Capital Markets on Lead Drug